What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Can include rhythm, melody, harmony, dynamics, texture, timbre and structure. of the music such as their melody close melodyDifferent pitched notes played one after another making a tune., ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Could a diabetes and weight loss drug benefit the brain? Here’s what scientists are learning. By Dana G. Smith and Dani Blum Over a decade ago, a smattering of studies suggested that early ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients ...

Ophthalmic complications were observed in patients using semaglutide and tirzepatide, but a causal link was not established. The study included nine patients, with conditions like nonarteritic ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...